Entropy and enthalpy in the activity of Tubulin-based antimitotic agents

Current Chemical Biology

Volumn 3, Issue 1, 2009, Pages 47-59

  Daly, Erin M ^a   Taylor, Richard E ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Antimitotic agents; Binding afftinity; Enthalpy; Entropy; Microtubules; Tubulin

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BETA TUBULIN; COLCHICINE; CYTOTOXIC AGENT; DICTYOSTATIN; DISCODERMOLIDE; DOCETAXEL; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; ESTRADIOL DERIVATIVE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; NOCODAZOLE; PACLITAXEL; PODOPHYLLOTOXIN; SARCODICTYIN A; SARCODICTYIN B; SULFONAMIDE A; SULFONAMIDE B; SULFONAMIDE C; SULFONAMIDE D; SULFONAMIDE E; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BINDING AFFINITY; BINDING SITE; BREAST CANCER; CLINICAL TRIAL; DRUG DESIGN; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENTHALPY; ENTROPY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MICROTUBULE; MICROTUBULE ASSEMBLY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS; THERMODYNAMICS;

EID: 65549161484     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231309787158244     Document Type: Review

References (147)

1. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol(TM). Drug Discov Today 2001; 6: 1153-64.
2. Dutcher SK. The tubulin fraternity: alpha to eta. Curr Opin Cell Biol 2001; 13: 49-54.
3. Fosket DE, Morejohn LC. Structural and functional organization of tubulin. Ann Rev Plant Physiol Plant Mol Biol 1992; 43: 201-40.
4. Burkhart CA, Kavallaris M, Horwitz SB. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001; 2: 1-9.
5. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 5803-9.
6. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005; 19: 1299-31.
7. Wilson L, Panda D, Jordan MA. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cell regulators. Cell Struct Funct 1999; 24: 329-35.
8. Altman K-H, Jurg G. Anticancer drugs from nature - natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007; 24: 327-57.
9. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Chapter 19: Cell moltility and shape II: Microtubules and intermediate filaments. In: Tenney S, editor. Molecular Cell Biology (4th ed). New York: W.H. Freeman & Co.; 2000.
10. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2: 1-17.
11. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Cancer Rev 2004; 4: 253-65.
12. Sengupta S, Thomas SA. Drug target interaction of tubulin-binding drugs in cancer therapy. Exp Rev Anticancer Ther 2006; 6: 1433-47.
13. Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008; 28: 155-83.
14. Beckers TL, Reissmann T, Schmidt M, et al. SU11464/D-69491, a selective and potent pan HER tyrosine kinase inhibitor (abstract 3884). Proc Am Assoc Cancer Res 2002; 43: 784.
15. Capraro HG, Brossi A. The Alkaloids. New York: Academic Press; 1984.
16. Cortese F, Bhattacharyya B, Wolff J. Podophyllotoxin as a probe for the colchicine binding site of tubulin. J Biol Chem 1977; 252: 1134-40.
17. Friedman PA, Platzer EG. Interaction of antihelminthic benzamidazole and benzamidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 1978; 554: 605-14.
18. Hastie SB, Puett D, McDonald TL, Williams RC. The binding of isocolchicine to tubulin. J Biol Chem 1989; 264: 6682-8.
19. Head J, Lee LL, Field DJ, Lee JC. Equilibrium and rapid kinetic studies on nocodazole-tubulin interaction. J Biol Chem 1985; 260: 11060-6.
20. Kirby S, Gertler SZ, Mason W, et al. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro-oncology 2005; 7: 183-8.
21. Leoni LM, Hamel E, Genini D, Shih H, Carrera CJ, Cottam HB. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst 2000; 92: 217-20.
22. Ni L, Meng CQ, Sikorski JA. Recent advances in therapeutic chalcones. Exp Opin Ther Pat 2004; 14: 1669-91.
23. Sengupta S, Smitha SL, Thomas NE, et al. 4-Amino-5-benzoyl-2- (4-methoxyphenylamino) thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system. Br J Pharmacol 2005; 145: 1076-83.
24. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Nintani H. Phase I study og E7010. Cancer Chemo Pharm 1998; 42: 127-34.
25. Cenciarelli C, Tanzarella C, Vitale I, et al. The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis 2008: 659-69.
26. Rappl C, Barbier P, Bourgarel-Rey V, et al. Interaction of 4- arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin. Biochemistry 2006; 45: 9210-8.
27. Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents 2002; 2: 55-70.
28. Jassem J, Kosmidis P, Ramlau R, et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 2003; 14: 1634-9.
29. Rossi A, Gridelli C, Gebbia V, et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003; 23: 1657-64.
30. Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E. Spongistatin I, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 1993; 44: 757-66.
31. Bai R, Taylor GF, Cichacz ZA, et al. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry 1995; 34: 9714-21.
32. Bai R, Taylor GF, Schmidt JM, et al. Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. Mol Pharmacol 1995; 47: 965-76.
33. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med Res Rev 1998; 18: 259-96.
34. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005; 4: 1086-95.
35. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH. Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett 1995; 377: 59-61.
36. Li Y, Kobayashi H, Tokiwa Y, Hashimoto Y, Iwasaki S. Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site. Biochem Pharmacol 1992; 43: 219-24.
37. Nunes M, Kaplan J, Wooters J, et al. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label-tubulin. Biochemistry 2005; 44: 6844-57.
38. Panda D, Ananthnarayan V, Larson G, Shih C, Jordan MA, Wilson L. Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochemistry 2000; 39: 14121-7.
39. Takahashi M, Iwasaki S, Kobayashi H, et al. Studies on macrocyclic lactone antibiotics. XI: Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues. J Antibiot 1987; 40: 66-72.
40. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-74.
41. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-7.
42. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
43. Bollag DM, McQueeny PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism. Cancer Res 1995; 55: 2325-33.
44. Edler MC, Buey RM, Marcus AJ, et al. Cyclostreptin (FR182877), a cytotoxic tubulin-polymerizing agent deficient in hypernucleating tubulin assembly. Biochemistry 2005; 44: 11525-36.
45. Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral derived natural products eleutherobin and sarcodityins A and B effects on the assembly purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999; 38: 5490-8.
46. Kowalski KJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reaxctions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-22.
47. Paterson I, Briton R, Delgado O, Meyer A, Poullennec KG. Total synthesis and configurational assignment of (-)-dictystatin, a microtubule-stabilizing macrolide of marine origin. Angew Chem Int Engl 2004; 43: 4629-33.
48. Wang Z, Yang D, Mohanakeishnan AK, et al. Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability. J Med Chem 2000; 43: 2419-29.
49. Day BW. Mutants yield a pharmacophore model for the tubulin-paclitaxel binding site. Trends Pharmacol Sci 2000; 21: 321-3.
50. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97: 2904.
51. Kingston DG, Bane S, Snyder JP. The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle 2005; 4: 279-89.
52. Kingston DGI. Taxol, a molecule for all seasons. J Chem Soc Chem Commun 2001; 2001: 867-80.
53. Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA 1999; 96: 4256.
54. Winkler JD, Axelsen PH. A model for the taxol (paclitaxel)/epothilone pharmacophore. Bioorg Med Chem Lett 1996; 6: 2963-6.
55. Gaitanos TN, Buey RM, Diaz JF, et al. Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug - resistant cell lines. Cancer Res 2004; 64: 5063-7.
56. Pryor DE, O'Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site kills cells resistant to paclitaxel and epothilones and may not require its epoxide moiety for activity. Biochemistry 2002; 41: 9109-15.
57. Tinley TL, Randall-hlubek DA, Leal RM, et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 2003; 63: 3211-20.
58. Madari H, Panda D, Wilson L, Jacobs RS. dicoumarol: a unique microtubule stabilizing natural product that is synergistic with taxol. Cancer Res 2003; 63: 1214-20.
59. Smith G, Neubauer B, Sundboom J, et al. Correlation of the in vivo coagulant, antithrombotic and metastatic efficacy of warfarin in the rat. Thromb Res 1988; 50: 163-74.
60. Miglietta A, Gabriel L, Appendino G, Bocca C. Biological properties of jatrophane polyesters, new microtubule-interacting agents. Cancer Chemo Pharm 2003: 67-74.
61. Marcus AI, Zhou J, O'Brate A, et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deactylase. Cancer Res 2005; 65: 3883-93.
62. Szwajkajzer D, Carey J. Molecular and biological constraints on ligand-binding affinity and specificity. Biopolymers 1997; 44: 181-98.
63. Ruben AJ, Kiso Y, Freire E. Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chem Bio Drug Des 2006; 67: 2-4.
64. Velazquez-Campoy A, Todd MJ, Freire E. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. Biochemistry 2000; 39: 2201-7.
65. Lafont V, Armstrong AA, Ohtaka H, Kiso Y, Mario Amzel L, Freire E. Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem Biol Drug Des 2007; 69: 413-22.
66. Cabani S, Gianni P, Mollica V, Lepori L. Group contributions to the thermodynamic properties of non-ionic organic solutes in dilute aqueous solution. J Solution Chem 1981; 10: 563-95.
67. Sharma S, Bharadwaj S, Surolia A, Podder S. Evaluation of the stoichiometry and energetics of carbohydrate binding to Ricinus communis agglutinin: a calorimetric study. Biochem J 1998; 333: 539-42.
68. Williams BA, Chervenak MC, Toone EJ. Energetics of lectin-carbohydrate binding. A microcalorimetric investigation of concanavalin A-oligomannoside complexation. J Biol Chem 1992; 267: 22907-11.
69. Lemieux RU, Du MH, Spohr U, Acharya S, Surolia A. Molecular recognition XIII. The binding of the H-type 2 human blood group determinant by a winged bean (Psophocarpus tetragonolobus) acidic lectin. Can J Chem 1994; 72: 158-63.
70. Puri KD, Surolia A. Thermodynamics of lectin-sugar interaction: binding of sugars to winged bean(psophocarpus tetragonolobus) basic agglutinin(WBAI). Pure Appl Chem 1994; 66: 497-502.
71. Gupta D, Cho M, Cummings RD, Brewer CF. Thermodynamics of carbohydrate binding to galectin-1 from Chinese hamster ovary cells and two mutants. A comparison with four galactose-specific plant lectins. Biochemistry 1996; 35: 15236-43.
72. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-49.
73. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches toestimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 1997; 23: 3-25.
74. Gigant B, Wang C, Ravelli RB, et al. Structural basis for the regulation of tubulin by vinblastine. Nature 2005; 435: 519-22.
75. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double blind study. N Engl J Med 1974; 291: 934-7.
76. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. A double-blind trial. N Engl J Med 1974; 291: 932-4.
77. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428: 198-202.
78. Wolff J, Knipling L, Cahnmann HJ, Palumbo G. Direct photoaffinity labeling of tubulin with colchicine. Proc Natl Acad Sci USA 1991; 88: 2820.
79. Banerjee A, D'Hoore A, Engelborghs Y. Interaction of desacetamidocolchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers alpha beta II, alpha beta III, and alpha beta IV. J Biol Chem 1994; 269: 10324-9.
80. Banerjee A, Luduena RF. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem 1992; 267: 13335-9.
81. Bane S, Puett D, Macdonald TL, Williams RC. Binding to tubulin of the colchicine analog 2-methoxy-5-(2′, 3′, 4′-trimethoxyphenyl) tropone. Thermodynamic and kinetic aspects. J Biol Chem 1984; 259: 7391-8.
82. Das L, Datta AB, Gupta S, et al. -NH-dansyl isocolchicine exhibits a significantly improved tubulin-binding affinity and microtubule inhibition in comparison to isocolchicine by binding tubulin through its A and B rings. Biochemistry 2005; 44: 3249-58.
83. Chattopadhyay S, Bisaria VS, Panda AK, Srivastava AK. Cytotoxicity of in vitro produced podophyllotoxin from podophyllum hexandrum on human cancer cell line. Nat Prod Res 2004; 18: 51-7.
84. Gordaliza M, Castro MA, del Corral JM, Feliciano AS. Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des 2000; 6: 1.
85. Yoshimatsu K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997; 57: 3208-13.
86. Gupta S, Das L, Datta AB, Poddar A, Janik ME, Bhattacharyya B. Oxalone and lactone moieties of podophyllotoxin exhibit properties of both the B and C rings of colchicine in its binding with tubulin. Biochemistry 2006; 45: 6467-75.
87. Chakrabarti G, Sengupta S, Bhattacharyya B. Thermodynamics of Colchicinoid-Tubulin Interactions. J Biol Chem 1996; 271: 2897.
88. Diaz JF, Andreu JM. Kinetics of dissociation of the tubulin-colchicine complex. J Biol Chem 1991; 266: 2890-6.
89. Banerjee M, Poddar A, Mitra G, Surolia A, Owa T, Bhattacharyya B. Sulfonamide drugs binding to the colchicine site of tubulin: thermodynamic analysis of the dok Drug-Tubulin interactions by isothermal titration calorimetry. J Med Chem 2005; 48: 547-55.
90. Kadkade PG. Growth and podophyllotoxin production in callus tissues of podophyllum-peltatum. Plant Sci Lett 1982; 25: 107-15.
91. Owa T, Okauchi T, Yoshimatsu K, et al. A focused compound library of novel N-(7-indolyl) benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg Med Chem Lett 2000; 10: 1223-6.
92. Owa T, Yokoi A, Yamazaki K, Yoshimatsu K, Yamori T, Nagasu T. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl) amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(-3chloro-7-indolyl)-1, 4-benzenedisulfonamide. J Med Chem 2002; 45:4913-22.
93. Owa T, Yoshino H, Okauchi T, et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 1999; 42: 3789-99.
94. Scheindlin S, Rubin N. Isolation of an alkaloid from Vinca-Minor. J Am Pharm Assoc (Wash) 1955; 44: 330-2.
95. Jordan MA. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 1991; 51: 2212-22.
96. Jordan MA, Wilson L. Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 1990; 29: 2730-9.
97. Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 1993; 32: 1285-93.
98. Lin CM, Hamel E. Effects of inhibitors of tubulin polymerization on GTP hydrolysis. J Biol Chem 1981; 256: 9242-5.
99. Rai SS, Wolff J. Localization of the Vinblastine-Binding site ontubulin. J Biol Chem 1996; 271: 14707-11.
100. Bhattacharyya B, Wolff J. Tubulin-Aggregation and disaggregation: mediation by two distinct Vinblastine-Binding sites. Proc Natl Acad Sci USA 1976; 73: 2375-8.
101. Wilson L. Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. Biochemistry 1970; 9: 4999-5007.
102. Wilson L, Morse AN. Characterization of acetyl-3H-labeled vinblastine binding to vinblastine-tubulin crystals. J Mol Biol 1978; 121: 255-68.
103. Lobert S, Frankfurter A, Correia JJ. Binding of vinblastine to Phosphocellulose-Purified and alpha/beta-Class iii tubulins: the role of nucleotides and beta-tubulin isotypes. Biochemistry 1995; 34: 8050-60.
104. Jordan MA, Margolis RL, Himes RH, Wilson L. Identification of a distinct class of vinblastine binding sites on microtubules. J Mol Biol 1986; 187: 61-73.
105. Singer WD, Jordan MA, Wilson L, Himes RH. Binding of vinblastine to stabilized microtubules. Mol Pharmacol 1989; 36: 366-70.
106. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996; 35: 6806-14.
107. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990; 265: 17141-9.
108. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 1999; 96: 5686.
109. Lobert S, Fahy J, Hill BT, Duflos A, Etievant C, Correia JJ. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry 2000; 39: 12053-62.
110. Tahir SK, Nukkala MA, Mozny NAZ, et al. Biological activity of a-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol Cancer Ther 2003; 2: 227-33.
111. Alami N, Paterson J, Belanger S, Juste S, Grieshaber CK, Leyland-Jones B. Comparative analysis of xanafide cytotoxicity in breast cancer cell lines. Br J Cancer 2007; 97: 58-64.
112. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7.
113. Choy H. Taxanes in combined modality therapy for solid tumors. Oncol Hematol 2001; 37: 237-47.
114. Caplow M, Shanks J, Ruhlen R. How taxol modulates microtubule disassembly. J Biol Chem 1994; 269: 23399-402.
115. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel driven polymerization. J Biol Chem 1997; 272: 17118-25.
116. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996; 6: 610-7.
117. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: a new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931-59.
118. Höfle G, Bedorf N, Gerth K, Reichenbach H. DE-4138042 (1993). Chem Abstr 1993; 120: 560-3.
119. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H. Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria) - Production, physico-chemical and biological properties. J Antibiot 1996; 49: 560-3.
120. Altmann KH. Epothilone B and its analogs-a new family of anticancer agents. Mini Rev Med Chem 2003; 3: 149-58.
121. Altmann KH. Recent developments in the chemical biology of epothilones. Curr Pharm Des 2005; 11: 1595-613.
122. Borzilleri RM, Vite GD. Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Fut 2002; 27: 1149-63.
123. Harris CR, Danishefsky SJ. Complex target T-oriented synthesis in the drug discovery process: a case history in the D-epo B series. J Org Chem 1999; 64: 8434-56.
124. Höfle G, Reichenbach H. Anticancer agents from natural products. In: Cragg M, Kingston DGI, Newman DJ, Eds. Boca Raton, FL: CRC Press LLC; 2005.
125. Nicolaou KC, Roschangar F, Vourloumis D. Chemical biology of epothilones. Angew Chem Int Ed Engl 1998; 37: 2014-45.
126. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2: 123-48.
127. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470: M79-M91.
128. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997; 272: 2534.
129. Buey RM, Diaz JF, Andreu JM, et al. Interaction of epothilone analogs with the paclitaxel binding site relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol 2004; 11: 225-36.
130. Buey RM, Barasoain I, Jackson E, et al. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol 2005; 12: 1269-79.
131. Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J Org Chem 1990; 55: 4912-5.
132. Gunasekera SP, Gunasekera M, McCarthy P. Discodermalide: a new bioactive macrocyclic lactam from the marine sponge Discodermia dissoluta. J Org Chem 1991; 56: 4830-3.
133. Hung DT, Jamison TF, Schreiber SL. Understanding and controlling the cell cycle with natural products. Chem Biol 1996; 3: 623-39.
134. ter Haar E, Kowalski RJ, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996; 35: 243-50.
135. Minguez JM, Giuliano KA, Balachandran R, Madiraju C, Curran DP, Day BW. Synthesis and high content cell-based profiling of simplified analogues of the microtubule stabilizer (+)-discodermolide. Mol Cancer Ther 2002; 1: 1305-13.
136. Martello LA, LaMarche MJ, He L, Beauchamp TJ, Smith AB, Horwitz SB. The relationship between taxol and (+)-discodermolide: synthetic analogs and modeling studies. Chem Biol 2001; 8: 843-55.
137. Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000; 6: 1978.
138. Huang GS, Lopez-Barcons L, Freeze BS, et al. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 2006; 12: 298-304.
139. Lindel T, Jensen PR, Fenical W, et al. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc 1997; 119: 8744-5.
140. Long BH. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 1998; 58: 1111-5.
141. McDaid HM, Johnston PG. Synergistic interaction between paclitaxel and 8-chloro-adenosine-3′, 5′-monophosphate in human ovarian carcinoma cell lines. Clin Cancer Res 1999; 5: 215-20.
142. D'Ambrosio M, Guerriero A, Pietra F. Sarcodictyin-A and sarcodictyin-B, novel diterpenoidic alcohols esterified by (E)-n (1)-methylurocanic acid-isolation from the Mediterranean stolonifer Sarcodictyon roseum. Helv Chim Acta 1987; 70: 2019-27.
143. Ketzinel S, Rudi A, Schleyer M, Benayahu Y, Kashman Y. Sarcodictyin A and two novel diterpenoid glycosides, eleuthosides A and B, from the soft coral Eleutherobia aurea. J Nat Prod 1996; 59: 873-5.
144. Nakao Y, Yoshida S, Matsunaga S, Fusetani N. (Z)-sarcodictyin A, a new highly cytotoxic diterpenoid from the soft coral Bellonella albiflora. J Nat Prod 2003; 66: 524-7.
145. D'Ambrosio M, Guerriero A, Pietra F. Isolation from coral Sarcodictyon roseum of sarcodictyin C, D, E, and F, novel diterpenoidic alcohols esterified by (E)-or (Z)-N (1)-methylurocanic acid. Helv Chim Acta 1988; 71: 964-76.
146. Ciomei M, Albanese C, Pastori W, et al. Sarcodictyins: a new class of marine derivatives with mode of action similar to Taxol. Proc Am Assoc Cancer Res 1997; 38: 5.
147. Beumer R, Bayon P, Bugada P, et al. Synthesis of novel simplified sarcodictyin/eleutherobin analogs with potent microtubule-stabilizing activity, using ring closing metathesis as the key-step. Tetrahedron 2003; 59: 8803-20.